medicines


MSF response on RCEP negotiations in the Philippines
Negotiators must protect public health safeguards that enable developing countries like India to keep supplying life-saving affordable medicines for millions of people worldwide.
Stop trading workers’ rights over profits
RCEP magnifies existing inequalities and discriminates against women, indigenous peoples, people living with HIV or other illnesses, people with disabilities,rural communities, farmers and workers
RCEP: Corporations could sue governments
ISDS is increasingly being used by global corporations to challenge health, environment and other public interest laws.
Employment crisis and free trade agreements( FTAs) : Why workers should reject RCEP
Trade unions, farmers groups, health activists, and other people’s movements are planning to organise a series of events to put pressure on the Government of India to withdraw from RCEP negotiations.
The expanding universe of IP
Granting data exclusivity for clinical trials would undermine access to medicines.
CETA bringing changes to pharma patents in Canada
A certificate of supplemental protection provides up to two years of additional protection after expiry of a patent.
Compulsory licensing in Colombia: Leaked documents show aggressive lobbying by Novartis
Confidential documents obtained by Public Eye show that Novartis has threatened Colombia with international investment arbitration under its BIT with Switzerland to avoid the issuance of a compulsory license
Gilead Pharma corp withdraws investment arbitration after Ukraine agrees to settlement of dispute over monopoly rights to market anti-viral drug
Ukraine has settled a dispute with American pharmaceutical company Gilead Sciences Inc., following the company’s pursuit of legal remedies in both domestic courts and via investment arbitration.
Proposed trade pact clause on intellectual property could endanger India's TB programme
A draft of the Regional Comprehensive Economic Partnership agreement reveals three clauses that could potentially hurt production of important generic drugs
Tribunal dismisses Eli Lilly’s NAFTA challenge on promise utility doctrine
The Tribunal found that Eli Lilly had failed to demonstrate that the promise doctrine constitutes a fundamental or dramatic change in the utility requirement under Canadian patent law or that the promise doctrine is arbitrary and/or discriminatory.